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Abstract
Background: Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy chances in women with
diminished ovarian reserve (DOR), and to reduce miscarriage rates by 50-80%. Such an effect is mathematically
inconceivable without beneficial effects on embryo ploidy. This study, therefore, assesses effects of DHEA on
embryo aneuploidy.
Methods: In a 1:2, matched case control study 22 consecutive women with DOR, supplemented with DHEA,
underwent preimplantation genetic screening (PGS) of embryos during in vitro fertilization (IVF) cycles. Each was
matched by patient age and time period of IVF with two control IVF cycles without DHEA supplementation (n =
44). PGS was performed for chromosomes X, Y, 13, 16, 18, 21 and 22, and involved determination of numbers and
percentages of aneuploid embryos.
Results: DHEA supplementation to a significant degree reduced number (P = 0.029) and percentages (P < 0.001)
of aneuploid embryos, adjusted for relevant covariates. Short term supplementation (4-12 weeks) resulted in
greatest reduction in aneuploidy (21.6%, 95% CI -2.871-46.031).
Discussion: Beneficial DHEA effects on DOR patients, at least partially, are the likely consequence of lower embryo
aneuploidy. DHEA supplementation also deserves investigation in older fertile women, attempting to conceive,
where a similar effect, potentially, could positively affect public health.
Background
Dehydroepiandrosterone (DHEA) has been demon-
strated to improve embryo quality and pregnancy
chances in women with diminished ovarian reserve
(DOR) [1-3]. How these effects are achieved is, however,
unknown. A small pilot study of limited power sug-
gested that DHEA may reduce aneuploidy [4]. Since
aneuploidy in human embryos is frequent and increases
with advancing female age [5,6], a reduction in aneu-
ploidy could, at least partially, explain improved embryo
quality and pregnancy rates.
Aneuploidy in preimplantation embryos can be
demonstrated through preimplantation genetic screening
(PGS) [7]. PGS is, however, only rarely indicated in
women with DOR, where often only small embryo
numbers are available, and embryo selection, therefore,
does not offer clinical benefits [8]. PGS in such cases
may, actually, reduce pregnancy chances with in vitro
fertilization (IVF) [9].
Our initial pilot study, attempting to investigate
DHEA effects on ploidy, was underpowered. In that
study we were able to demonstrate that DHEA supple-
mented patients had greater chances of at least one
euploid embryo. The study, likely because of small
patient numbers, however, failed to demonstrate signifi-
cant decreases in overall aneuploidy [4].
For lack of adequate PGS case numbers, we, therefore,
pursued an alternative strategy by investigating miscar-
riage rates after DHEA supplementation as a surrogate
for aneuploidy risk [10]. Since at least 60 percent of
spontaneous pregnancy loss is attributable to chromoso-
mal abnormalities [11], we hypothesized that significant
reductions in aneuploidy after DHEA supplementation
should be reflected in lower miscarriage rates. This was,
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indeed, confirmed in a study, involving patients from
two independent centers in New York City and Tor-
onto, Canada [10].
While results of this study were strongly supportive of
a DHEA effect on aneuploidy, they were unable to offer
direct evidence, which can only come from PGS studies
of human embryos. Such a study is presented here.
Methods
Patient populations
We retrieved from our center’s computerized research
data bank a total of 22 consecutive DOR patients who
underwent IVF/PGS while on DHEA supplementation.
Only first IVF cycles were analyzed. These cycles were
matched with the two control cycles not on DHEA sup-
plementation, based on patient age and year of treat-
ment (44 controls). Primary medical records for all of
these patients were pulled and manually reviewed by
one of the authors (A.W.).
A diagnosis of DOR was reached if patients demon-
strated abnormally elevated age-specific baseline follicle
stimulating hormone (FSH) or abnormally low age-spe-
cific anti-Müllerian hormone (AMH) levels. Normal
age-specific hormone levels were defined by 95% confi-
dence intervals at all ages, as previously reported
[12,13]. Since patients with DOR were, thus, uniformly
diagnosed before IVF cycle protocols were determined,
they were all supplemented with DHEA, and stimulation
adjustments were made. As we previously reported, this
results in improved oocyte and embryo yields in com-
parison to patients who are not diagnosed with use of
age-specific FSH and AMH [12,13].
DHEA supplementation
During the study period all DOR patients at our center
routinely received DHEA supplementation [14]. Those
not receiving DHEA, therefore, by definition, had age-
appropriate ovarian reserve, confirmed by normal anti-
Müllerian hormone (AMH), follicle stimulating hor-
mone (FSH) baseline levels and estradiol. Patients
receiving DHEA supplementation were prescribed 25
mg of micronized, pharmaceutical grade DHEA, T.I.D,
for at least four weeks prior to IVF cycle start [14].
Short-term supplementation was defined as 4 to 12
weeks of DHEA prior to IVF and PGS; supplementation
beyond that was considered long-term supplementation.
Ovarian stimulation
Patients with premature DOR, or if over 40 years of age,
in first treatment cycles universally receive a so-called
microdose gonadotropin releasing hormone agonist
(GnRH-a) ovarian stimulation protocol, characterized by
leuprolide acetat (50 μg/0.1 mL, b.i.d.; Lupron®, Abbot
Pharmaceuticals, North Chicago, IL) and ovarian
stimulation with follicle stimulating hormone (FSH, 300
IU-450 IU daily) and human menopausal gonadotropins
(hMG, 150 IU). If under age 40 with normal ovarian
reserve patients receive down regulation with full dose
GnRH-a (1.0 mg/0.1 mL) and ovarian stimulation with
up to 300 IU of gonadotropins, usually half as FSH and
half as hMG. Higher luteinizing hormone (LH) contri-
butions to ovarian stimulation, if anything, reduce
embryo aneuploidy [15]. The small difference in ovarian
stimulation protocols between women with DOR and
controls, therefore, potentially biases study outcome
towards lower aneuploidy rates in the control popula-
tion, which received a proportionally higher LH contri-
butions to ovarian stimulation.
Preimplantation genetic screening (PGS)
PGS was performed, utilizing fluorescence in situ hybri-
dization (FISH) in routine fashion, utilizing probes for
seven chromosomes (X, Y, 13, 16, 18, 21 and 22) on day
three after fertilization, when embryos reached six to
eight cell stages. This restricted chromosome panel is
currently routinely utilized for PGS [15].
Statistical analysis
A general linear model was constructed to assess DHEA
effects on percent aneuploidy after adjustment for age,
indications for PGS, stimulation protocol and total
gonadotropin dosage utilized. The latter adjustment was
made as a surrogate for potential physician biases in
how individual patients were stimulated, and potential
effects such stimulation biases may have on ploidy
[15,16].
All patients at our center sign a universal informed
consent at time of initial presentation, which permits
the extraction of clinical data from patient records as
long as confidentiality of the record and anonymity of
patients is maintained. The center’s Institutional Review




Table 1 summarizes characteristics of study and control
patients. The two groups did not differ in age and race/
ethnicity. DHEA patients were significantly more obese
but expressed poorer ovarian reserve, based on lower
AMH (P = 0.045) and significantly higher gonadotropin
utilization (P = 0.002). Such a conclusion was also sup-
ported by trends towards higher FSH and smaller oocyte
yields (9.6 ± 6.2 vs. 11.7 ± 6.3). Embryo numbers trans-
ferred (1.4 ± 0.9 vs. 1.5 ± 0.7), embryos cryopreserved
(0.7 ± 1.6 vs. 0.6 ± 1.2), embryos undergoing PGS (7.3 ±
3.9 vs. 6.6 ± 3.6) and embryo grades (3.4 ± 0.4 vs. 3.5 ±
0.3) were similar between both groups.
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Aneuploidy
As Figure 1, however, demonstrates, aneuploid embryos
were significantly more prevalent amongst controls (4.5
± 3.1 vs. 2.8 ± 2.5; P = 0.03), as were percentages of
aneuploidy (61.0 ± 22.4 vs. 38.2 ± 24.4; P < 0.001). In
the general linear model, after adjustment for age, FSH
dose and indication for PGS, the association of DHEA
supplementation effects on ploidy remained significant
(F = 13.2, df 1, p = 0.001). As expected, women who
underwent PGS for aneuploidy screening had a greater
percentage of aneuploidy embryos than women who
underwent PGS for elective gender selection purposes
(P < 0.007).
Possibly because of still relatively small study num-
bers, no specific aneuploidy pattern, affecting distinct
chromosomes, was apparent.
Mean length of DHEA supplementation was 7.3 ± 2.2
weeks in the short and 19.1 ± 9.1 weeks in the long
treatment group. Women in the short treatment group
demonstrated the greatest reduction in aneuploidy
(21.6%, 95%CI -2.871-46.031).
Discussion
This study supports prior preliminary evidence that
DHEA supplementation reduces aneuploidy in women
with DOR, first suggested in a small pilot study, when
at least one euploid embryo was found significantly
more frequently after DHEA than in matched control
cycles [4]. Subsequently, we also demonstrated that
DHEA supplementation reduces miscarriage rates to a
degree that cannot be explained without significant con-
tribution from reduced aneuploidy [10].
By demonstrating no difference in embryo grades
between DHEA and control cycles (Table 1), this study
also demonstrates, once more, that embryo morphology,
as currently routinely assessed in most IVF laboratories,
does not reflect on embryo ploidy and, therefore, is lim-
ited in clinical value.
Since a majority of miscarriages are believed to be
consequence of aneuploidy [11], decreases in aneuploidy
rate should translate into decreases in spontaneous
pregnancy loss. Two infertility centers utilizing DHEA
supplementation, one in New York City and the other
in Toronto, Canada, indeed, independently, reported
identically low miscarriage rates of 15.0 and 15.2 per-
cent, respectively. Depending on method of statistical
analysis, these miscarriage rates represented declines of
approximately 50 to 80 percent from expectations [10].
Even more remarkably, the combined loss rate of 15.1
percent equated rates reported for normal populations
as young as 28 to 33 years [17], and was, thus, far




Age (years, Mean ± SD) 37.9 ± 4.7 37.2 ± 4.4 N.S.
Race/ethnicity (%)
Caucasian 14 (63.6) 21 (47.7)
African 2 (9.1) 3 (6.8)
Asian 4 (18.2) 14 (31.8)
Middle Eastern 1 (4.5) 6 (13.6)
BMI (Mean ± SD) 24.4 ± 3.8 21.0 ± 1.7 0.006
AMH (ng/mL, mean ± SD) 1.3 ± 1.2 2.0 ± 1.9 0.045
Range 0.8 - 2.1 1.0 - 4.4
FSH (mIU/mL, mean ± SD) 10.1 ± 6.8 8.0 ± 5.5 N.S.
Range 8.4 - 12.2 7.1 - 9.1
Oocytes retrieved (n, mean ± SD) 9.6 ± 6.2 11.7 ± 6.3 N.S.
Embryos (n, mean ± SD)
Transferred 1.4 ± 0.9 1.5 ± 0.7
Cryopreserved 0.7 ± 1.6 0.6 ± 1.2
Undergoing PGS 7.3 ± 3.9 6.6 ± 3.6
Grades 3.4 ± 0.4 3.5 ± 0.3
Total gonadotropins






1 Difference in BMI was based on significant difference in weight (P = 0.02)
not height (P = 0.24)
Figure 1 Comparison of absolute and percentages of
aneuploidy in DHEA and control patients.
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removed from excessively high miscarriage rates,
reported in DOR patients [18].
Even though such significant declines in spontaneous
miscarriages cannot be achieved without underlying
improvements in aneuploidy, miscarriage rates only
represent surrogates for true aneuploidy studies. Direct
evidence for such an effect was, therefore, still needed.
In this study we for the first time are able to demon-
strate such direct evidence, utilizing routinely performed
PGS of preimplantation stage embryos, performed in
DHEA supplemented IVF cycles and controls. DHEA
supplementation was, indeed, associated with signifi-
cantly reduced aneuploidy, and greatest reductions were
observed with short DHEA supplementation of up to 12
weeks.
This observation on first impulse suggests that,
excluding month one of supplementation, second and
third months offer the best chance of lowering aneu-
ploidy, thus fully supporting previously published preg-
nancy data after DHEA supplementation, which
demonstrated a significant first rise in pregnancy rate
after approximately six weeks of DHEA supplementation
[14]. Six weeks of DHEA supplementation prior to IVF
cycle start, therefore, currently represents minimal sup-
plementation time at our center.
This study, however, does not preclude, as alternative
explanation for these findings that a more favorable
patient group conceives quickly and, therefore, statisti-
cally distorts above noted time associations. Such a pos-
sibility cannot be ruled out since we previously
demonstrated that women who improve AMH levels
with DHEA supplementation demonstrate significantly
superior pregnancy rates to those who do not [19].
A general criticism of currently available technologies
for PGS is that only limited numbers of chromosomes
can be evaluated (24 chromosome screening technolo-
gies are currently under investigation). In this study this
meant that only seven chromosomes were assessed in
study and control patients. This allows for the at least
theoretical possibility that untested chromosomes
demonstrate statistically different aneuploidy distribu-
tions from the here tested seven and that, including a
full chromosome complement, here reported differences
would disappear. Such an explanation is, however,
highly unlikely, and the here utilized selection of chro-
mosomes, or similar ones, have been routinely used in
clinical PGS [15,16]. There is also no data in either
human or animal literature to suggest that DOR maybe
associated with aneuploidy of specific chromosomes.
Because of time pressures, when using their own
oocytes, prospectively randomized clinical trials in
patient populations affected by DOR, and involving pla-
cebo, are difficult, if not impossible, to conduct. Our
center, for that reason, had to abandon two registered
clinical DHEA trials, one in the United States and one
in Europe, due to lack of enrollment [14]. A small first
such trial has just been reported [3]. Best available evi-
dence, therefore, at least in part, has to be obtained via
other study formats.
In this study, the format chosen was a case control
study in which each study patient/cycle was matched
with two controls. As Table 1 demonstrates, patient and
control populations appear, with few exceptions, overall
comparable. It is, however, important to point out that
the significantly larger preponderance of DOR in the
study group (Table 1) biases study results against dis-
covery of DHEA effects on ploidy since DOR patients
demonstrate the highest aneuploidy rate amongst infer-
tility patients [18]. Even just absence of increased aneu-
ploidy in the study group could, therefore, be viewed as
a potentially positive DHEA effect. Instead, this study
actually demonstrates significantly lower aneuploidy fol-
lowing DHEA supplementation.
How DHEA affects non-dysfunctional events remains
to be determined but we have speculated that DHEA
supplementation may improve the ovarian environment
in which follicular maturation takes place in older
women [19 and submitted]. DHEA, indeed, significantly
declines with advancing age [20]. Since DHEA, except in
our prior pilot study [4], has never before been directly
associated with decreases in aneuploidy, neither animal
nor human data are currently available to speculate
further on specific mechanisms that may be involved.
Others have speculated that drugs can be developed
which beneficially affect non-dysjunctional events during
meiosis [21]. DHEA may, indeed, turn out to be a first
pharmacologic agent to do so.
This effect, only unlikely, should be restricted to infer-
tile women with DOR. DHEA supplementation, in
attempts to reduce embryo aneuploidy and spontaneous
miscarriages, therefore, also deserves investigation in,
especially older (above age 35 years) fertile women,
attempting conception. A possible similar beneficial
impact in fertile patient populations, attempting sponta-
neous conception, could have a major impact on public
health by speeding up time to pregnancy and by redu-
cing embryo aneuploidy and miscarriage rates.
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